
Molecular medicine to individualise the treatment of metastatic cancer
UCAM has created Spain's first chair in this discipline, directed by Dr Fernando Vidal Vanaclocha, who describes the work he is carrying out in this interview.
Search in:
UCAM has created Spain's first chair in this discipline, directed by Dr Fernando Vidal Vanaclocha, who describes the work he is carrying out in this interview.
Its International Chair in Evaluative and Expert Medicine has analysed the impact of this disease on working women, due to its high incidence and the fact that, despite the good prognosis in most cases, it causes sequelae and difficulties to return to work.
Through an economic contribution or by disseminating the project it is possible to collaborate to this research, included in the FECYT Precipita platform (Spanish Ministry of Science and Innovation), which aims at developing a screening system through artificial intelligence that would reduce by 85% the pathologist’s workload, thus allowing to implement a population programme of early diagnosis. It is developed by researchers of UCAM Universidad Católica San Antonio de Murcia, the Polytechnic University of Valencia, the CIAGO Gynaecological Clinic of Torre Pacheco and the Santa Lucía and Santa María del Rosell university hospitals of Cartagena.
The recipients of the awards are Javier Bernal, for the best academic record of the Bachelor’s Degree in Medicine, Begoña Alburquerque, Carmen Lucas and Rebeca González, for their researches on the treatment of colorectal cancer and male baldness
The development of this patent has been possible thanks to the study carried out by UCAM and the IMIB to find new drugs that act by reducing the migration and invasion of tumour cells
The researchers belong to the Universidad Católica de Murcia, the Murcian Institute of Biosanitary Research and the University of Granada.
UCAM and Fundación Jiménez Díaz develop a project led by Dr. Óscar Aguilera that provides important results regarding the use of Vitamin C in the treatment of tumours resistant to chemotherapy.
Personal Data
The processing of personal data responsible entity is SAN ANTONIO UNIVERSITY FOUNDATION (Fundación Universitaria San Antonio). Your personal data will be processed in the information and guidance management activities, answer to your enquiries and promotional communications linked to this institution. Treatment legal base is your approval and agreement. Your data will be indefinitely retained until cancellation is requested. You can find more information about Privacy Policy through www.ucam.edu . You can contact the Data Protection Officer through dpd@ucam.edu. You have the right of access to this information, correct it, cancel it and other rights contained in LOPD (Legal Protection Act) and rules of procedure EU 2016/679 through the University Secretary, either in person or in writing, by confirming identification through secretaria@ucam.edu.
For more information you can visit our website terms and Conditions